Arbutus Biopharma Corp Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Arbutus Biopharma Corp (ABUS) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 1.59% for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-05.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2020-03-05
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2016-03-31 was 0.78%.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2019 was 1.59%, a 35.89% decline from fiscal 2018.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2018 was 2.48%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|
| 2019-12-31 | 1.59% 10-K · filed 2020-03-05 | ||||
| 2018-12-31 | 2.48% 10-K · filed 2020-03-05 | ||||
| 2016-09-30 | 0.66% 10-Q · filed 2016-11-03 | ||||
| 2016-06-30 | 0.88% 10-Q · filed 2016-08-04 | ||||
| 2016-03-31 | 0.78% 10-Q · filed 2016-05-04 | ||||
| 2016-01-01 | 0.86% 10-Q · filed 2016-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |